Exploring CDK4-6 Inhibitors Toxicities and Second-Line Treatment Options

Exploring the toxicities of palbocyclib, abemacyclib, and ribocyclib in metastatic breast cancer treatment, including neutropenia, GI tract issues, QTC prolongation, and pneumonitis. Additionally, discussing second-line treatment options for metastatic ER+/HER2- breast cancer, focusing on mutations like PIC3CA and drug choices like alpelisib and XMS stain with everolimus.